Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~* Metastatic disease~* Prior treatment with taxanes in the metastatic, adjuvant, or neoadjuvant setting~  * Taxane-resistant disease allowed regardless of duration of prior therapy NOTE: Resistant disease defined as progression during or within 12 weeks after taxane therapy for metastatic disease or a disease-free interval of less than 12 months after neoadjuvant or adjuvant therapy with a taxane~ * Taxane-sensitive disease allowed if at least 4 prior courses were received NOTE: Sensitive disease defined as progression occurring more than 12 weeks after taxane therapy for metastatic disease or more than 12 months after neoadjuvant or adjuvant therapy with a taxane~* Prior treatment with anthracyclines for metastatic disease or as adjuvant treatment OR medical contraindication to treatment with anthracyclines~* At least one unidimensionally measurable lesion (phase II study)~* No CNS metastases~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Female~Menopausal status~* Not specified~Performance status~* Karnofsky 70-100%~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Bilirubin no greater than 1.25 times upper limit of normal (ULN)~* Transaminases no greater than 2.5 times ULN (5 times ULN if liver metastases present)~Renal~* Creatinine clearance greater than 50 mL/min~Cardiovascular~* No symptomatic ventricular arrhythmias~* No clinically significant congestive heart failure~* No clinical or ECG evidence of myocardial infarction within the past 12 months~* No significant coronary artery disease~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No prior malignancy within the past 5 years except contralateral breast cancer, nonmelanoma skin cancer, and adequately treated carcinoma in situ of the cervix~* No known or prior sensitivity to fluoropyrimidines, including fluorouracil~* No pre-existing grade 2 or greater neurotoxicity~* No known malabsorption or upper gastrointestinal abnormalities that would affect absorption of study drug~* No psychological, familial, sociological, or geographical condition that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent biologic therapy~Chemotherapy~* See Disease Characteristics~* No more than 2 prior chemotherapy lines for metastatic disease~* No prior capecitabine, vinca alkaloids, or continuous fluorouracil~* No other concurrent chemotherapy~Endocrine therapy~* Prior hormonal therapy allowed~* No concurrent hormonal therapy~Radiotherapy~* No concurrent radiotherapy~Surgery~* Not specified~Other~* Bisphosphonate therapy for treatment and prevention of bony metastases allowed if initiated prior to study~* No other concurrent investigational treatment~* No concurrent brivudine with capecitabine

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues